Recommended

New Webinar: Neurological disorders – organoids for early drug discovery
Listen to our latest podcast: breaking resistance – the future of immunotherapy in oncology
Download now: The latest advancements and breakthroughs in immuno-oncology
Register now: Ion Channel Drug Discovery – Recent Advances in Novel Non-Opioid Pain Research
Register now: SAFIRE: AI predicted ADME for drug discovery: leveraging bioprint
webinar

Chasing my Cure: Leveraging serum proteomics to identify novel therapeutic approaches and predictive biomarkers

Watch our on-demand one-hour session to discover groundbreaking work to advance precision medicine for Castleman disease.

About this webinar

Dr David Fajgenbaum, the Founding Director of the Center for Cytokine Storm Treatment & Laboratory at the University of Pennsylvania and national bestselling author of Chasing My Cure: A Doctor’s Race to Turn Hope Into Action, shares his groundbreaking work to advance precision medicine for Castleman disease, a cytokine storm disorder that he is battling as a physician, researcher, advocate and patient. Combining SomaScan proteomic and other -omic analyses with cutting-edge bioinformatic approaches, Fajgenbaum has discovered novel predictive biomarkers of treatment response and novel treatment approaches, including one that is saving his life and others.

Learning outcomes of this webinar

  • The potential for unbiased serum proteomic analyses to improve understanding of the pathologic mechanisms of a poorly understood, inflammatory disease (idiopathic multicentric Castleman disease)
  • How SomaScan can be leveraged to discover biomarkers that can predict which patients will respond to a given treatment
  • How SomaScan can be leveraged to identify novel therapeutic targets and promising new or repurposed treatment approaches
  • The importance of academic-industry-advocacy collaborations to leverage biospecimens collected from clinical trials to improve understanding and treatment of rare disorders.

Our speaker

David Fajgenbaum for Wharton MagazineDavid Fajgenbaum, MD, MBA, MSc
Assistant Professor of Medicine, Translational Medicine & Human Genetics, University of Pennsylvania
Founding Director, Center for Cytokine Storm Treatment & Laboratory (CSTL)
Associate Director, Patient Impact, Orphan Disease Center, University of Pennsylvania
Co-Founder & President, Castleman Disease Collaborative Network (CDCN)

David Fajgenbaum, MD, MBA, MSc, is an Assistant Professor of Medicine at the University of Pennsylvania, Founding Director of the Center for Cytokine Storm Treatment & Laboratory (CSTL), Associate Director of Patient Impact for the Penn Orphan Disease Center and co-Founder/President of the Castleman Disease Collaborative Network (CDCN). He is also the national bestselling author of ‘Chasing My Cure: A Doctor’s Race to Turn Hope Into Action’ and a patient battling idiopathic multicentric Castleman disease (iMCD). He is in his longest remission ever thanks to a precision treatment that he identified, which had never been used before for iMCD. Fajgenbaum launched the CORONA project in March 2020 to identify and track treatments for COVID-19. Today, CORONA is the world’s largest database of COVID-19 treatments, including more than 400 medications that have been administered to more than 280,000 patients. Fajgenbaum has published scientific papers in high-impact journals such as the New England Journal of Medicine, Journal of Clinical Investigation and Blood. To advance drug repurposing, he is co-directing an FDA/NIH/C-Path public-private partnership called the CURE Drug Repurposing Collaboratory and leading an effort for rare disease repurposing in collaboration with the Chan Zuckerberg Initiative.